Zealand plans €100 million IPO
This article was originally published in Scrip
Zealand Pharma, the Danish peptide drug discovery company, has announced plans to raise up to €104 million at a pre-money valuation of between €215 million and €300 million in an IPO on the NASDAQ OMX Exchange in Copenhagen. This would be the largest Scandinavian life sciences IPO since 2000 and the first one outside of France this year. It would also more than double the amount raised by European life science companies in an IPO this year (see table).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.